Key result
Prostacyclin inhibits the development of platelet prothrombinase activity by preventing the formation of a negatively charged phospholipid surface on the platelet membrane.
Why the study?
Does prostacyclin inhibit platelet prothrombinase activity?
Does prostacyclin inhibit platelet prothrombinase activity?
Prostacyclin inhibits platelet prothrombinase activity by preventing the formation of a procoagulant phospholipid surface, independent of thromboxane A2 formation.
Answers are grounded in this paper and cite their sources.
Prostacyclin may inhibit platelet procoagulant activity independently of thromboxane; leaves open clinical translation in thrombosis.
Prostacyclin is able to inhibit the development of platelet prothrombinase activity. This inhibition, which also occurs with dibutyryl cAMP, is presumably due to the ability of prostacyclin to prevent the formation of a negatively charged phospholipid surface at the exterior half of the platelet membrane. Generation of this procoagulant surface, as induced by platelet activation with collagen plus thrombin, does not depend on thromboxane A2 formation.
No takes yet. Share an insight, caveat, or question.
Zwaal et al. (2009) studied this question. Prostacyclin was evaluated on Platelet prothrombinase activity. Prostacyclin inhibits the development of platelet prothrombinase activity by preventing the formation of a negatively charged phospholipid surface on the platelet membrane.
Synapse has enriched 10 related papers. Consider them for comparative context: